Test Price
2,800 AED✅ Home Collection Available
TERT Gene Germline Mutation Analysis for AML Susceptibility (NGS)
Executive Summary & Core Metrics
- Diagnostic Sensitivity: 99.9% across TERT coding and regulatory regions via ISO 9001:2015-accredited workflow.
- Specimen Collection: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection, available daily from 8 AM to 11 PM.
- Post-Test Genetic Counseling: One-on-one telephonic consultation with a board-certified genetic specialist to review results and familial implications.
- Insurance Verification: Direct billing confirmation via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The TERT Gene Germline Mutation Analysis for AML Susceptibility is a highly sensitive genetic test that detects inherited pathogenic variants in the TERT gene associated with hereditary acute myeloid leukemia (AML) predisposition. Our targeted next-generation sequencing (NGS) panel with Sanger validation delivers precise risk stratification for patients and at-risk family members, enabling proactive hematological surveillance and personalized clinical management.
| Feature | Our Test (NGS TERT AML Panel) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity for TERT coding and regulatory regions | ~97%, variable coverage; incidental findings common |
| Methodology | Targeted NGS + Sanger validation | Broad exome capture, bioinformatics-heavy |
| Turnaround Time | 3–4 weeks | 6–10 weeks |
Physician Insight & Safety Protocols
“A positive TERT germline mutation result identifies a hereditary predisposition to AML, not an active leukemia diagnosis. Lifelong hematological surveillance, family cascade testing, and lifestyle modifications are essential follow-up measures. This finding must always be contextualised within a three-generation pedigree and interpreted through formal genetic counseling.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
This test evaluates inherited genetic risk only. Do not alter or discontinue any prescribed treatment regimen without consulting your primary hematologist or oncologist. Results do not replace ongoing clinical monitoring or acute care protocols.
Exclusion Criteria & Emergency Red Flags
- This test is not intended as a standalone diagnostic tool for individuals currently receiving active AML therapy.
- Patients with known inherited bone marrow failure syndromes must obtain hematologist approval before proceeding.
- Seek immediate emergency care if you experience: unexplained bruising or bleeding, persistent high fever, extreme fatigue, or recurrent infections — these may signal acute leukemia onset.
Patient FAQ & Clinical Guidance
1. What is the TERT gene germline mutation test for AML susceptibility?
This molecular test uses next-generation sequencing to detect inherited DNA variants in the TERT gene that substantially elevate lifetime risk for acute myeloid leukemia. Analysis is performed on a peripheral blood sample to identify pathogenic mutations associated with familial AML syndromes, enabling early surveillance and risk-reduction planning for patients and their first-degree relatives.
2. How should I prepare for this genetic test, and what sample is required?
No fasting is necessary. The preferred sample is 5 mL of whole blood collected in an EDTA tube, though extracted DNA or a dried blood spot on an FTA card is also acceptable. A mandatory pre-test genetic counseling session is required to document a three-generation family pedigree and obtain informed consent in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
3. Is this test covered by UAE insurance, and what do results mean for my family?
We provide direct insurance billing verification via WhatsApp; many UAE health policies include hereditary cancer risk testing for qualifying families. A pathogenic result indicates a 50% probability that each first-degree relative carries the same mutation, which supports cascade screening and tailored surveillance programs to reduce AML morbidity and mortality.
UAE Regulatory & Data Privacy Adherence
All genetic testing and patient data handling at DNA Labs UAE strictly comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and informed consent procedures are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genomic data remains confidential and is used solely for diagnostic interpretation and risk assessment.
Clinical & Logistical Metadata
| Test Name | TERT Gene Germline Mutation Analysis for AML Susceptibility (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (5 mL EDTA) — VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, Available Daily from 8 AM to 11 PM |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) + Sanger Validation |
| ICD-10-CM Code | Z15.09 |
| LOINC Code | 88253-5 |
| DHA Facility License & Laboratory Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians